Cas:1233024-97-9 4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate manufacturer & supplier

We serve Chemical Name:4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate CAS:1233024-97-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-Cyano-3,5-difluorophenyl 4'-ethyl-[1,1'-bi(cyclohexane)]-4-carboxylate

Chemical Name:4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate
CAS.NO:1233024-97-9
Synonyms:4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate
Molecular Formula:C22H27F2NO2
Molecular Weight:375.4520864
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate Use and application,4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate technical grade,usp/ep/jp grade.


Related News: Ultimately there’s likely a broad mix of social, cultural and economic drivers at play, suggested Lona Sandon, program director of the Department of Clinical Nutrition in the School of Health Professions at the UT Southwestern Medical Center in Dallas. She was not part of the research. 4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate supplier The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months. 4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate vendor The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development. 4-Cyano-3,5-difluorophenyl 4′-ethyl-[1,1′-bi(cyclohexane)]-4-carboxylate factory The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.